Literature DB >> 12902517

Prevention of collagen-induced arthritis in mice transgenic for the complement inhibitor complement receptor 1-related gene/protein y.

Nirmal K Banda1, Damian M Kraus, Michele Muggli, Alison Bendele, V Michael Holers, William P Arend.   

Abstract

The objective of these studies was to examine collagen-induced arthritis (CIA) in C57BL/6 mice transgenic for the rodent complement regulatory protein complement receptor 1-related gene/protein y (Crry) (Crry-Tg), a C3 convertase inhibitor. The scores for clinical disease activity and for histological damage in the joints were both significantly decreased in Crry-Tg mice in comparison to wild-type (WT) littermates. The production of both IgG1 and IgG2a anti-collagen Abs was reduced in the Crry-Tg mice, although spleen cell proliferation in response to collagen type II was not altered. The production of IFN-gamma, TNF-alpha, and IL-1beta by LPS-stimulated spleen cells was decreased, and IL-10 was increased, in cells from Crry-Tg mice in comparison to WT. The steady-state mRNA levels for IFN-gamma, TNF-alpha, and IL-1beta were all decreased in the joints of Crry-Tg mice in comparison to WT. The synovium from Crry-Tg mice without CIA contained the mRNA for the Crry transgene, by RT-PCR, and the synovium from transgenic mice with CIA exhibited little deposition of C3 protein by immunohistological analysis. These results suggest that suppression of CIA in Crry-Tg mice may be due to enhanced synthesis of Crry locally in the joint with decreased production of proinflammatory cytokines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12902517     DOI: 10.4049/jimmunol.171.4.2109

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Increased serum C3 levels in Crry transgenic mice partially abrogates its complement inhibitory effects.

Authors:  H J Kang; L Bao; Y Xu; R J Quigg; P C Giclas; V M Holers
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

2.  Dual role of shikonin in early and late stages of collagen type II arthritis.

Authors:  Qiaomei Dai; Jianghong Fang; Feng-shan Zhang
Journal:  Mol Biol Rep       Date:  2008-09-10       Impact factor: 2.316

3.  Role of soluble Fas ligand in autoimmune diseases.

Authors:  Ning-Li Li; Hong Nie; Qi-Wen Yu; Ji-Ying Zhang; An-Lun Ma; Bai-Hua Shen; Li Wang; Jun Bai; Xue-Hua Chen; Tong Zhou; Dong-Qing Zhang
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

4.  Therapeutic effect of low-dose IL-18 combined with IL-10 on collagen-induced arthritis by down-regulation of inflammatory and Th1 responses and induction of Th2 responses.

Authors:  Qiaomei Dai; Yang Li; Fengshan Zhang; Haiyue Yu; Xiaoyan Wang
Journal:  Rheumatol Int       Date:  2008-10-09       Impact factor: 2.631

5.  Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice.

Authors:  Nirmal K Banda; Brandt Levitt; Magdalena J Glogowska; Joshua M Thurman; Kazue Takahashi; Gregory L Stahl; Stephen Tomlinson; William P Arend; V Michael Holers
Journal:  J Immunol       Date:  2009-10-14       Impact factor: 5.422

6.  Complement regulatory protein Crry deficiency contributes to the antigen specific recall response in experimental autoimmune myasthenia gravis.

Authors:  Jindrich Soltys; Xiaobo Wu
Journal:  J Inflamm (Lond)       Date:  2012-05-29       Impact factor: 4.981

7.  A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis.

Authors:  Kenneth J Katschke; Karim Y Helmy; Micah Steffek; Hongkang Xi; Jianping Yin; Wyne P Lee; Peter Gribling; Kai H Barck; Richard A D Carano; Robin E Taylor; Linda Rangell; Lauri Diehl; Philip E Hass; Christian Wiesmann; Menno van Lookeren Campagne
Journal:  J Exp Med       Date:  2007-06-04       Impact factor: 14.307

Review 8.  Complement in the Initiation and Evolution of Rheumatoid Arthritis.

Authors:  V Michael Holers; Nirmal K Banda
Journal:  Front Immunol       Date:  2018-05-28       Impact factor: 7.561

9.  Toll-Like Receptor 4-Myeloid Differentiation Primary Response Gene 88 Pathway Is Involved in the Shikonin Treatment of CIA by Regulating Treg/Th17 Expression.

Authors:  Qiaomei Dai; Ji Li; Yu Yun; Jianwei Wang
Journal:  Evid Based Complement Alternat Med       Date:  2018-12-16       Impact factor: 2.629

10.  C2 IgM Natural Antibody Enhances Inflammation and Its Use in the Recombinant Single Chain Antibody-Fused Complement Inhibitor C2-Crry to Target Therapeutics to Joints Attenuates Arthritis in Mice.

Authors:  Nirmal K Banda; Stephen Tomlinson; Robert I Scheinman; Nhu Ho; Joseline Ramos Ramirez; Gaurav Mehta; Guankui Wang; Vivian Pham Vu; Dmitri Simberg; Liudmila Kulik; V Michael Holers
Journal:  Front Immunol       Date:  2020-10-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.